关于美国最近结束了二..干眼症领域或将出现一个专门针对睑板腺功能障碍(MGD)的药物。Azura公司实验中的新药AZR-MD-001于2022年末完成了二期临床测试,预计于今年三月开启第三轮临床测试。一直以来对于MDG的治疗
Azura is currently conducting a multi-center, double-masked, vehicle-controlled Phase 2b study that will evaluate the safety and efficacy of AZR-MD-001 in patients with MGD. Primary endpoints will include patient-reported symptoms as measured by the Ocular Surf...
3. Results and discussion 3.1. Alloy design and microstructure characterization 3.1.1. CALPHAD simulation The predicted equilibrium phase mole fraction versus temperature for equiatomic TiNbTaZrMo and TiNbTaZrMoV HEAs are shown in Fig. 1(a) and (b), respectively. As shown in Fig. 1(a), the...